Tumefactive demyelination presenting during bevacizumab treatment

We report the emergence of tumefactive demyelination during treatment with intravitreal bevacizumab (Avastin). This is of particular significance given that bevacizumab is currently being assessed as a potential treatment option for neuromyelitis optica, another demyelinating condition.

Na minha lista:
Detalhes bibliográficos
Publicado no:BMJ Case Rep
Main Authors: Rice, Claire M, Rossiter, David, Fehmi, Janev, Stevens, James C, Renowden, Shelley A, Cohen, Nicki, Bailey, Clare, Scolding, Neil J
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4691864/
https://ncbi.nlm.nih.gov/pubmed/26677151
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2015-212173
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados